전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
vorikonasoolravi alustamisel
patients already on ciclosporin it is
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
vorikonasoolravi alustamisel patsientidel, kes juba saavad ravi tsüklosporiiniga, on
when initiating voriconazole in patients already on ciclosporin it is recommended
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
raskes üldseisundis patsientidel on vorikonasoolravi korral täheldatud ägedat neerupuudulikkust.
acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
vorikonasoolravi alustamisel patsientidel, kes juba saavad raviks takroliimust, on viimase
in patients already on tacrolimus, it is recommended that the tacrolimus dose be
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
561 patsiendil vältas vorikonasoolravi enam kui 12 nädalat, neist 136- l enam kui 6 kuud.
five hundred and sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over 6 months.
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
kui vorikonasoolravi ajal ilmneb nahalööve, tuleb haiget hoolikalt jälgida ja nahalööbe progresseerumisel ravi katkestada.
if patients develop a rash they should be monitored closely and vfend discontinued if lesions progress.
마지막 업데이트: 2012-04-11
사용 빈도: 2
품질:
kliinilistes uuringutes vältas vorikonasoolravi 705 patsiendil enam kui 12 nädalat, neist 164 said vorikonasooli enam kui 6 kuud.
in clinical trials, 705 patients received voriconazole therapy for greater than 12 weeks, with 164 patients receiving voriconazole for over 6 months.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
29-päevase raviperioodi vältel ei täheldatud vabatahtlikel erg muutuste progresseerumist ja need taandusid täielikult vorikonasoolravi lõpetamisel.
the erg changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
29-päevase raviperioodi vältel ei täheldatud vabatahtlikel elektroretinogrammis täheldatud muutuste progresseerumist ja need taandarenesid täielikult vorikonasoolravi lõpetamisel.
the erg changes did not progress over 29 days of treatment and were fully reversible on withdrawal of voriconazole.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
35 kui vorikonasoolravi ajal tekib nahalööve, tuleb haiget hoolikalt jälgida ja nahakahjustuse süvenemisel ravi vfend’ iga kohe katkestada.
if patients develop a rash they should be monitored closely and vfend discontinued if lesions progress.
마지막 업데이트: 2012-04-11
사용 빈도: 4
품질:
enamikul juhtudest normaliseerusid maksafunktsiooni testid vorikonasoolravi käigus kas ravimi annust vähendamata või seda vähendades (sealhulgas ravi katkestades).
the majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
raviga seotud kõrvaltoimete korral peab kaaluma vorikonasoolravi lõpetamist ja teiste seenevastaste ravimite kasutamist (vt lõigud 4.4 ja 4.8)
in the case of treatment-related adverse events, discontinuation of voriconazole and use of alternative antifungal agents must be considered (see section 4.4 and 4.8)
마지막 업데이트: 2017-04-26
사용 빈도: 2
품질:
enne vorikonasoolravi ja ravi ajal tuleb jälgida ja vajadusel korrigeerida elektrolüütide häired nagu hüpokaleemia, hüpomagneseemia ja hüpokaltseemia (vt lõik 4.2).
electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.2).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
enne ravi alustamist ja vorikonasoolravi ajal tuleb jälgida ja vajadusel korrigeerida elektrolüütide häired nagu hüpokaleemia, hüpomagneseemia ja hüpokaltseemia (vt lõik 4.4).
electrolyte disturbances such as hypokalaemia, hypomagnesaemia and hypocalcaemia should be monitored and corrected, if necessary, prior to initiation and during voriconazole therapy (see section 4.4).
마지막 업데이트: 2017-04-26
사용 빈도: 4
품질:
raske põhihaigusega patsientidel on vorikonasoolravi ajal harvade juhtudel täheldatud tõsist maksakahjustust, kaasa arvatud ikterust, hepatiiti ja surmani viinud maksapuudulikkust (vt lõik 4. 4).
this includes cases of jaundice, and rare cases of hepatitis and hepatic failure leading to death (see section 4.4).
마지막 업데이트: 2011-10-23
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
elektrolüütide tasakaalu häired (hüpokaleemia, hüpomagneseemia ja hüpokaltseemia) tuleb korrigeerida enne vorikonasoolravi alustamist (vt lõigud 4.2 ja 4.4).
electrolyte disturbances such as hypokalemia, hypomagnesemia and hypocalcemia should be corrected prior to initiation of voriconazole therapy (see sections 4.2 and 4.4).
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
patsiente, eriti lapsi, kellel esinevad ägeda pankreatiidi riskitegurid (nt hiljutine keemiaravi või vereloome tüvirakkude transplantatsioon (hsct, haematopoietic stem cell transplantation)), tuleb vorikonasoolravi ajal hoolikalt jälgida.
patients, especially children, with risk factors for acute pancreatitis (e.g., recent chemotherapy, haematopoietic stem cell transplantation (hsct)), should be monitored closely during voriconazole treatment.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질: